Chronic anemia of cancer can be corrected in approximately 50% of the cases by treatment with recombinant human erythropoietin (rHuEPO1. Early prediction of responsiveness would avoid the emotional and financial burden of ineffective medical intervention. Eighty patients with chronic anemia of cancer undergoing treatment with rHuEPO (150 U/kg, 3 times per week by subcutaneous injection; after 6 weeks without response, 300 U/kgl participated in this study. Response was defined as a gain of at least 2 g/dL hemoglobin (Hb) within 12 weeks. Multivariate discriminant analysis and logistic regression analysis of response were performed on routine blood tests; serum levels of EPO, iron, ferritin, transferrin, and its receptor; World Health Organization (WHO) performance status; various cytokines; neopterin; stem cell factor; C-reactive protein; and a,-antitrypsin. At baseline,
crine therapy,' and, more recently, predictive factors have also become available for liver and lung fibrosis after autologous bone marrow tran~plantation.~ Early or late response to rHuEPO treatment as opposed to treatment failure has most recently been predicted for patients with anemia of chronic renal failure. '" In the present study, we investigated the power of hematologic parameters and humoral factors, including cytokines and acute-phase proteins, to predict response to rHuEPO therapy in anemia of cancer either in advance or during the early stages of treatment.
MATERIALS AND METHODS

Patients.
Eighty consecutive patients with chronic anemia of cancer who qualified for treatment with rHuEPO (baseline hemoglobin [Hh] level < l 1 g/dL, clinical symptoms of anemia, exclusion of other possible causes of anemia, no blood transfusion within the last 2 weeks, and a life expectancy greater than 3 months) participated in the study. This unselected patient group presented with a variety of both hematologic malignancies (20 patients with multiple myeloma, 6 with myelodysplastic syndrome, 4 with chronic lymphocytic leukemia, 4 with non-Hodgkin's lymphoma, and 3 with Hodgkin's disease) and solid tumors (19 patients with breast cancer, 7 with gastrointestinal cancer, 6 with lung cancer, 3 with head and neck cancer, 3 with ovarian cancer, 3 with prostate cancer, I with renal cancer, and 1 with melanoma). Patient characteristics are listed in Table I .
During the first 2 weeks of rHuEPO treatment, 6 patients received chemotherapy (3 in the test group and 3 in the verification group), and I patient (in the test group) had to be irradiated. Transfusions of packed red blood cells (RBCs) were necessary in 4 nonresponders (2 in the test group and 2 in the verification group), but in none of the patients who eventually responded to the treatment. Death during the 12-week evaluation period for response (earliest death after 4 weeks) occurred in 21 patients (test group, 4 responders and 7 nonresponders; verification group, 1 responder and 9 nonresponders).
Treatment regimen. rHuEP0 (specific activity, 110.048 U/mg hormone; Cilag CO, Vienna, Austria) was administered subcutaneously 3 times a week at an initial dosage of 150 UAcg body weight. If by week 6 the Hb level had failed to improve to at least 2 g/dL above baseline, the dosage was increased to 300 UAcg; after the achievement of Hb concentrations within the normal range, individual dosage reductions were allowed. This protocol has been accepted Srudy design. The search for optimal prognostic parameters involved three major steps. First, all data from all patients (baseline values, absolute values after 1 and 2 weeks of therapy, and the changes observed after 1 and 2 weeks) were correlated with response, and stepwise discriminant analyses were performed on the various 1057 bodies of data. This first step of evaluation yielded several independent prognostic parameters.
Next, the patient population was split into two subgroups. In chronological order, the patients were alternately assigned to either the test group or the verification group. The two subgroups did not differ significantly in any of the observed patient characteristics ( Table 1) . Only the test group was used to generate a predictive algorithm. For each of the variables selected in step one, the optimal cutpoint was determined by applying stepwise discriminant analysis on a set of possible stratifications at various percentiles. The resulting optimal cutpoints were rounded for practical reasons. Multivariate logistic regression rendered the algorithm with high predictive power for response as well as failure to respond to rHuEPO therapy.
Because impressive results of regression analysis principally prove only that the results have been fitted well to the existing data, we used the independent data of the second subgroup of patients to verify the predictive power of the algorithm derived from the test group. The subsequent analysis of survival times (data that had not been included in any of the previous evaluations) could safely be performed on the entire patient population.
Srarisrical evaluation. The significance of differences between quantitative data was determined by means of the nonparametric Kruskal-Wallis test; for categorical data, the x' test or Fisher's exact test were used, appropriately. Correlations between quantitative variables and the qualitative variable "response" were calculated as point-biserial correlations. The stepwise discriminant analysis used stepwise selection of independent variables that contributed significantly to the discriminatory power of the model as measured by Wilks' lambda, the likelihood ratio criterion. Multivariate regression analysis applied Cox's maximum likelihood logistic regression model." Where possible, the odds ratios were calculated according to Mantel-Haenszel. For contingency tables that contained a zero, the odds ratios were determined by means of corrected logit estimators. The significance of differences between stratified Kaplan-Meier survival curves were calculated according to Mantel-Cox and Breslow. Bonferroni statistics were applied to multiple comparisons of single data sets. The statistical evaluation was performed with the aid of an IBM model 3090 computer.
RESULTS
Prognostic value of single factors. Correlation analyses
showed that none of the investigated variables were associated strongly enough with response to serve as a reliable single prognostic factor (Table 2) . At baseline, only the serum level of endogenous EPO proved to be significantly, but rather weakly correlated with response. This result could not be improved by considering the patient's degree of anemia (ie, expressing endogenous EPO as U/g Hb; r = 0.259). None of the common patient characteristics (eg, duration of malignant disease, previous and current cancer treatment, bone marrow involvement, hematologic malignancy versus solid tumor) was a useful indicator of responsiveness to rHuEPO (data not shown). One week of rHuEPO therapy had not yet effected sufficient changes from the baseline values (data not shown). However, after 2 weeks of treatment, 12 variables showed significant correlations. The best indicator of response was the change in Hb concentration after 2 weeks; however, with a correlation coefficient of r = 0.554, it still cannot be used as a sole prognostic factor.
Stepwise discriminant analysis.
The results of stepwise discriminant analysis are shown in Table 3 . As expected from the correlation results, the serum level of EPO was For personal use only. on October 3, 2017. by guest www.bloodjournal.org From the only baseline variable that discriminated significantly between future responders and nonresponders. After 2 weeks of rHuEPO treatment, the observed change in Hb and absolute Hb values proved to be the best discriminators. The only other independent variables with discriminatory power were the absolute serum levels of EPO and those of ferritin. Because the analysis was multivariate, only the independent proportions of ? are listed in the results. If Hb accounts for 36% of the total variance, information about the serum level of EPO will add 15%, and data on serum ferritin will improve the discrimination by yet another 14%. The result of the combination of change in Hb and absolute serum level of EPO was the first indicator of a realistic possibility of predicting the outcome of rHuEPO treatment (correlation with response; r = 0.715).
Logistic regression analysis.
From the data of the test group, the following optimal cutpoints were derived for the main predictive variables (rounded for practical reasons): serum level of EPO less than 100 mU/mL versus 2 100 mu/ mL, change in Hb level to less than 0.5 g/dL versus 20.5 g/dL, and serum concentration of ferritin less than 400 ng/ mL versus 2400 ng/mL (cutpoints of the other variables not shown). Multivariate logistic regression analysis of the complete stratified data yielded the same independent significant variables as did the discriminant analysis of the quantatitive data (serum level of EPO, P < .01; change in Hb level, P < .02; and serum concentration of ferritin, P < Predictive algorithm.
The algorithm developed to achieve high predictive power within a standard clinical setting is shown in Fig 1. It applies to patients who have received rHuEPO therapy for 2 weeks and offers two options.
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If possible, the combination of serum EPO level and the change in Hb level is evaluated. First, one determines whether the patient shows both negative signs of an EPO level greater than or equal to the cutpoint and a change of Hb level less than the cutpoint. In this case, response to rHuEPO treatment is very unlikely (Table 4 , first section). Only 10% of our responding patients in the test group and 5% in the verification group manifested the combination of both negative predictors.
If the condition defined above is not met, chances are good that the patient will respond to rHuEPO therapy. A total of 79% of our responders in the test group and 82% of those in the verification group belonged to this category. The predictions are significant, and the odds ratios high (Table  4) .
Because the prediction of response as derived from the failure to meet the negative condition (change in Hb level to less than 0.5 g/dL and in serum EPO level to 2 100 mu/ mL) will on the average be false in 1 of 5 cases, a check should be made as to whether the predictive power can be improved. Equivalent to the negative condition, there exists a positive condition consisting of the combination of an EPO level less than the cutpoint and an increase in Hb level to greater than or equal to the cutpoint. It is associated with a very high probability of response to rHuEPO treatment (Table 4, second section). None of our nonresponders, either in the test group or in the verification group, met this condition. Again, the prediction was significantly correct, and the odds ratios were high. By applying this second step, the predictive power could be greatly improved in 42% of our patients who had been classified as future responders by their failure to meet the negative condition.
In case the measurement of serum EPO levels is not possible, we offer a second option, namely the evaluation of serum ferritin levels less than 400 ng/mL versus those greater than or equal to that cutpoint (Table 4 , third section). High serum levels of ferritin were found in 75% and 100% of our nonresponders in the test group and in the verification group, respectively. Significance and the odds ratios of this secondline tool for decision-making are still satisfactory. The accuracy of predicted failure to respond is acceptable, but predicted response shows a relatively high proportion of error (false prognosis in approximately 1 of 4 patients.) r----. ferritin < 400 ng/ml Clinical application of the algorithm. Table 5 shows the ease of the clinical use of the algorithm by taking our entire patient group as an example. Only one step is required for decision-making. If both the serum level of EPO and the increment of the Hb concentration after 2 weeks are available, the treatment is either stopped or continued according to cutpoints. The discontinuation will be false in 1 of 15 patients, and 1 of 5 patients treated further will fail to respond within 12 weeks.
The option to predict response (shown on the right-hand side of Fig 1) confirms the decision to continue the treatment in 15 of 45 (33.3%) patients, who all (100%) responded. Though it is mainly of theoretical interest, it could also aid decision-making under unfavorable conditions when sparse rHuEPO supplies require a stringent patient selection.
Some small treatment facilities may find it difficult to obtain the findings of serum EPO concentrations promptly. In that case, measurements derived after 1 week of therapy may be substituted without much loss of predictive power (87.0% for unresponsiveness, when serum EPO concentration after l week is 2 100 mU/mL and the change in Hb level after 2 weeks is less than 0.5 g/dL; 95% for response, when serum EPO concentration after 1 week is less than 100 mU/mL and the change in Hb level after 2 weeks is greater than or equal to 0.5 g/dL; data not shown).
The second choice shown in Table 5 , decision-making according to serum ferritin levels, is clearly inferior to the first choice. Of 8 patients, 1 will be denied a potentially beneficial treatment, and 1 of 4 patients will be treated without success.
Survival times. Because survival was significantly ( P < .005) longer in our responding patients (median survival time, 12.6 months) than in our nonresponders (median survival time, 4.3 months), we used survival times as an independent factor to confirm the prognostic power of the predictive algorithm. Figure 2 shows the distinct differences between survival in patients with predicted response and those for whom no response was predicted ( P < .05 for positive versus negative condition; P < .01 for stratification according to ferritin levels).
DISCUSSION
Evaluation of baseline values showed that none of the 21 variables that had been selected as possible prognostic factors discriminated sufficiently between future response to rHuEPO therapy and lack of response. Several investigators have reported that baseline serum levels of endogenous EPO greater than 500 mU/mL strongly indicate unrespons i v e n e~s .~~"~ These findings were confirmed by our data, because the baseline EPO levels of all responders remained less than 300 mU/mL (data not shown). However, the value of 500 mU/mL ranged almost exactly at the 95th percentile of EPO values in the entire patient group, rendering reliable predictions (ie, the prognosis of unresponsiveness) for only 5% of the patient population.
It has long been recognized that anemia of chronic disease involves several pathologic processes including shortened RBC survival, hyporesponsiveness of the bone marrow to the increased demand on erythropoiesis, and impaired release of iron from normal or overloaded stores." Anemia associated with cancer is believed to be partly caused by insufficient EPO production.l"18 In the context of predicting response to substitution therapy with rHuEPO, we searched not only for possible indicators of a blunted EPO response to the anemic condition but also for signs of other known suppressors of erythropoiesis. Various cytokines, alone or interacting with each other and/or with additional factors, have been described as influencing erythropoiesis. IL-lp,I9.'O TNF,I9.'l and IFN-yZ2 have been reported to suppress erythropoiesis in vitro as well as in vivo by acting s y n e r g i s t i~a l l y~~~~~ and enhancing each others' e x p r e s s i~n .~~~~~ In addition, all three cytokines inhibit the release of iron from the reticuloendothelial system.26 IL-1 and TNF inhibit hypoxia-induced EPO production, whereas L 6 seems to stimulate it.I9 The results of animal and in vitro experiments, namely the reversal of TNF-a-induced anemia in mice" and the correction of cytoFor personal use only. on October 3, 2017. by guest www.bloodjournal.org From kine-induced suppression of colony-forming unit-erythroid growth2x by increased doses of exogenous EPO, have triggered the hypothesis that extremely high levels of inhibitory cytokines in nonresponding patients might require EPO levels higher than can be pharmacologically attained.26 Our results do not refute this hypothesis, because we did observe extremely high values of one or the other cytokine in some of our nonresponding patients. However, there was no clear pattern that would have allowed for reliable predictions. Serum levels of neopterin, which are elevated in a variety of malignant indicate the degree of activation of cellular immunity29 (ie, stimulation of macrophages by IFNy.)" Its production is synergistically amplified by TNF." Neopterin levels have been reported to correlate with IFNy'2 and to correlate inversely with Hb and iron concentration^.'^ The latter finding led to the hypothesis of an association between the degree of activation of macrophages and the development of anemia by a shift of iron towards the storage sites.33 Thus, neopterin levels seemed to be a promising possible factor for prognosis in chronic anemia of cancer. Another obvious choice as input into the predictive model were acute-phase proteins. They reflect episodes of inflammation and infection, which are common clinical complica- tions in cancer patients and often trigger chronic anemia. In addition, acute-phase proteins influence iron-related physiologic processes. CRP has been shown to correlate inversely with iron absorption,34 and serum levels of a,-antitrypsin were observed to be progressively increased in relation to tumor staging.'s a,-Antitrypsin competitively inhibits the binding of transferrin to its receptor,36 apparently by decreasing the affinity rather than the density of the binding sites for transferrin." Transferrin receptors have been included in our investigation because they serve as a measure of the degree of functional iron deficiency" and have been used to assess the extent of erythropoiesis."
Our results, namely the absence of powerful predictors of response among the investigated baseline variables, do not necessarily indicate that responsiveness to rHuEPO is completely independent of these parameters. The results rather mirror the average clinical situation that requires therapeutic decision-making for a series of consecutive patients with chronic anemia associated with a large variety of cancer types at various stages of progession and with different previous cancer treatments. Our present knowledge of chronic anemia of cancer does not offer rational criteria for the stratification of that heterogeneous patient collective into meaningful subgroups. Because chronic anemia of cancer is be-
lieved to involve several pa tho mechanism^,'^^^'^^^ some patients may be more severely affected by one and some by another. The resulting heterogeneity of the patient population would be very difficult to resolve by solely empirical means. rHuEPO treatment of certain types of cancer, such as multiple myeloma38 and the mainly cis-or carboplatin-treated squamous cell cancer,39 renders relatively high response rates, whereas treatment tends to fail in other types, such as myelodysplastic syndrome."' Besides extremely high EPO levels, these few selected diagnostic entities may, at present, be the best predictors before the start of therapy. However, in our study, comparisons of all diagnostic subgroups that contained a reasonable number of patients yielded no significant differences in any of the investigated variables (data not shown). More knowledge about the exact nature of chronic anemia of cancer as well as of the processes induced by exogenous EPO is urgently needed.
In contrast to baseline values, the data collected after 2 weeks of rHuEPO therapy rendered a simple and highly reliable predictive algorithm. This is not surprising, because the biologic changes observed at the time of response, which in chronic anemia of cancer generally occurs after 4 to 6 weeks of treatment, must be initiated at a much earlier stage of the treatment course. Predictions at 2 weeks are best derived from the observed changes in Hb levels and in the current serum level of EPO (total predictive accuracy of option 1 in Fig 1, 85.5% ). Alternatively, serum ferritin levels allow mainly the prediction of failure to respond to the treatment (total predictive accuracy of option 2, 78.8%).
Changes in Hb level seem to be a trivial measure, because response has been defined in terms of exactly these changes. Still, signs of increased erythrocyte production not only reflected the ultimate aim of the treatment but also proved to be the best indicator of responsiveness in multivariate analysis. Because they failed to contribute any predictive power beyond that already contained in the information about a pa- tient's Hb level, serum levels of neopterin, CRP, iron, transferrin and its receptor, and other prognostic variables were eliminated by stepwise discriminant analysis. Apparently, these factors change (directly or inversely) in close connection with the extent of de novo Hb synthesis.
Unfortunately, the criteria for response to rHuEPO therapy have not yet been internationally standardized. Some work groups use an increase in Hct of at least 6 percentage points as the response criterion.' Evaluation of our own data showed that our algorithm, which predicts an increase of at least 2 g/dL Hb, closely approximates an equivalent of 7.5 percentage points of Hct and should, therefore, also be an excellent predictor of response, as defined by 6% increase in Hct.
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As previously reported,* serum levels of EPO remain relatively stable in responders but increase in nonresponders during rHuEPO therapy. Therefore, after 2 weeks of treatment, serum EPO levels discriminated quite well between future responders and nonresponders. The approximate median value could be used as the cutpoint, rendering prediction possible for the entire patient population. Because the pattern of changes in EPO levels differs from that for Hb levels, predictive power is enhaced by considering both factors. Apparently, the processes of stimulated erythropoiesis in responders consume the substituted EPO, whereas exogenous EPO seems to accumulate in nonresponders. The latter is in accordance with the observation that EPO production is exclusively regulated at the gene level and, therefore, is independent of its plasma c~ncentration.~' Serum levels of ferritin are strongly associated with the extent of bone marrow iron store^.'^ Characteristic for chronic anemia of cancer and other chronic diseases are low levels of serum iron in spite of normal iron stores:* the socalled functional iron deficiency that can be experimentally induced in mice by TNF.4' Successful treatment of anemic patients with rHuEPO has resulted in significant decreases of ferritin levels and iron storesu The majority of our patients who, after 2 weeks of rHuEPO therapy, had retained serum levels of ferritin above 400 ng/mL were nonresponders. Even though these results are highly significant, the specific cutpoint may not apply to patients under heavy iron substitution therapy and needs to be confirmed or modified by other treatment centers.
Serum levels of transferrin receptors, which have been reported to increase significantly during successful rHuEPO treatment44 and helped to predict response in anemic patients with chronic renal failure," were eliminated from the model during stepwise discriminant analysis. Similar to the serum levels of transferrin and iron, they did not add significantly to the predictive power already contained in values of Hb and serum ferritin levels.
Because the results of regression analysis are always strongly dependent on the input data, we verified our predictive algorithm by means of an independent patient sample. The high reliability achieved by this method is encouraging. In addition, survival curves of responders and nonresponders, which have been shown to differ significantly,* could be discriminated well by our algorithm. In fact, the failure to gain sufficiently in Hb during the early stage of rHuEPO therapy combined with a relatively high serum level of EPO could possibly serve as an additional indicator of poor prognosis. Regardless of those first verification results, the model definitely needs to be confirmed in patients from different treatment centers before its application to individual patients can safely be recommended.
As long as neither the pathogenic mechanisms of chronic anemia of cancer are sufficiently known nor the processes of efficient rHuEPO treatment completely understood, prediction of response to rHuEPO therapy in patients with chronic anemia of cancer requires an empirical approach. We offer a highly predictive algorithm that depends on two measures that are routinely performed in most large treatment centers. Should findings of EPO serum levels not be available, ferritin may serve as an acceptable alternative. Without a doubt, the prediction of response and the early termination of unsuccessful treatment attempts in almost certainly unresponsive patients not only benefit the patients but also improve medical care through an economic use of its ever scarcer resources.
